5 minute read
NEWS
from REP Feb 21
Industry News
Henry Schein Medical helps automate, streamline patient waiting room process with Yosi Health
Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (Melville, NY), recently entered into a distribution agreement with Yosi Health, a provider of digital patient scheduling, registration, payment, and communication cloud-based software solutions.
According to Henry Schein, for physicians and patients looking for a streamlined waiting room process, Yosi Health’s patient intake solution, Yosi Intake, can create a contactless waiting room by enabling patients to register at home, helping to improve the patient experience and reduce administrative costs for the practice.
Integrated with industry-leading electronic medical record (EMR) and practice management solutions, Yosi Intake and Henry Schein can help deliver a customizable digital solution for scheduling and document management, as well as co-pays and payments.
As a result of this partnership, Yosi Health expands Henry Schein Medical’s SolutionsHub to help fulfill the clinical, financial, and operational needs of primary care physicians and specialists, group practices, physicianowned labs, ambulatory surgery centers, and Integrated Delivery Networks (IDNs)/Health Systems.
Tenet to sell urgent care platform to FastMed
Tenet Healthcare (Dallas, TX) and FastMed Urgent Care announced they have entered into a definitive agreement under which FastMed will purchase Tenet’s urgent care platform, which is operated under the CareSpot and MedPost brands and managed by Tenet’s United Surgical Partners International (USPI) subsidiary.
FastMed is one of the nation’s largest independent urgent care providers with 104 locations in North Carolina, Arizona and Texas. The transaction will add 87 CareSpot and MedPost centers, increasing patient access to FastMed’s healthcare services in Arizona and Texas, while enabling the company to expand into Florida and California where most of the acquired centers are located.
The transaction is expected to be completed in the first quarter of 2021, subject to regulatory approvals and customary closing conditions.
Thermo Fisher Scientific completed the acquisition of Phitonex, Inc. (Durham, NC), a company that has pioneered a spectral dye platform for high-resolution biology applications designed to accelerate research and development in cell therapy, immuno-oncology and immunology research.
Phitonex’s product offering will enable Thermo Fisher to offer greater flow cytometry and imaging multiplexing capabilities to meet evolving customer needs in protein and cell analysis research, the company says.
The Phiton platform acts as a structure that can maintain a higher number of fluorescent dyes in very specific ways, allowing researchers the ability to analyze single cells in high resolution. This allows researchers to achieve deeper biological insights and more comprehensive data from their cell samples.
With the ability to rapidly create a multitude of different dye labels, research teams can significantly increase the number of proteins and cell populations that can be identified in a single flow cytometry experiment.
“Phitonex’s platform is a natural extension of Thermo Fisher’s existing tools for protein and cell analysis applications,” said Peter Silvester, SVP and president of life sciences solutions at Thermo Fisher Scientific. “Combining this new technology with our existing portfolio and expertise in this space will unlock the Phiton platform’s great potential and deliver unparalleled flow cytometry performance so our customers can gain more valuable insights from a single cell and expedite discovery.”
Mercury Medical forms U.S. distribution agreement with Medovate
Mercury Medical (Clearwater, FL) has formed an agreement with Medovate (UK) to distribute its medical device SAFIRA (SAFer Injection for Regional Anesthesia) regional anesthesia device in the U.S.
SAFIRA is an FDA-cleared Class II medical device “set to transform regional anesthesia around the world by making it a one-person procedure,” the company says. The device puts control of the injection in the hands of the anesthesiologist, freeing up assistants to carry out other tasks. The company also says the device helps to improve patient safety by reducing the risk of nerve damage as it prevents injection above 20psi.
Mercury Medical will distribute SAFIRA throughout 28 U.S. states. This will cover the East Coast, the Southern states and the West Coast including the states of New York, Delaware, Florida, New Jersey, North Carolina, South Carolina, Texas, Mississippi and California.
Abbott’s BinaxNOW COVID-19 rapid test receives FDA emergency use authorization
Abbott (Abbott Park, IL) announced in December that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for virtually guided at-home use of its BinaxNOW COVID-19 Ag Card rapid test for detection of COVID-19 infection.
Abbott is bringing BinaxNOW, a rapid test, into the home where the result is delivered in minutes without the need to send it out for processing. The $25 cost for the test and service is the lowest currently available for at-home testing, Abbott says.
To facilitate the delivery of the BinaxNOW test to the home and the guided collection and testing process, Abbott has partnered with digital health solutions provider, eMed. Abbott and eMed expect to deliver and administer 30 million BinaxNOW at-home tests in the first quarter of 2021, with an additional 90 million in the second quarter.
Since launching BinaxNOW in August, Abbott has ramped up capacity to 50 million tests a month in its U.S. facilities that are currently being distributed through the federal government and is expanding further so even more people have access to the tests.
The eMed service offering costs $25 a test, and eMed takes care of determining eligibility, the guided self-collection process, public health reporting requirements and gets people their results through their NAVICA app in a matter of minutes.
Through eMed and the NAVICA app, people can use authenticated BinaxNOW results to enter into venues that accept the NAVICA digital certificate. The virtually guided process preserves the integrity of the testing process and state-mandated reporting obligations, while ensuring equitable access to people who need tests through the prescription process.
Don’t Be Fooled By Imitators
Don’t let imitators fool you in the new year, ensure you have authentic infection prevention products.
Increasing global demand for gloves and PPE created a tidal wave of inexperienced and unreliable entrepreneurs entering the marketplace, sourcing and marketing products without provenance, quality or proven compliance in the US.
“In times like these you must protect yourself and your customers by ensuring they have the authentic, reliable infection prevention products needed.”
Ventyv® is the premier brand of Sri Trang USA, Inc., a member of the Sri Trang Group. Sri Trang is a proven glove producer that has been protecting the world against infection since 1991.
